BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28345594)

  • 1. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy.
    Yu SL; Xu LT; Qi Q; Geng YW; Chen H; Meng ZQ; Wang P; Chen Z
    Sci Rep; 2017 Mar; 7():45194. PubMed ID: 28345594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
    Qi Q; Geng Y; Sun M; Wang P; Chen Z
    Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
    Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
    Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.
    An X; Ding PR; Li YH; Wang FH; Shi YX; Wang ZQ; He YJ; Xu RH; Jiang WQ
    Biomarkers; 2010 Sep; 15(6):516-22. PubMed ID: 20602543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?
    Hurmuz P; Ozyigit G; Kilickap S; Esen CSB; Akdogan B; Ozen H; Akyol F
    Urol Oncol; 2021 Jun; 39(6):368.e19-368.e29. PubMed ID: 33189528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio
    Chen Y; Liao Y; Lam LM; He L; Tsang YS; Di YS; Liang ST; Xia Q
    Int J Med Sci; 2020; 17(10):1449-1457. PubMed ID: 32624701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
    Lee BM; Chung SY; Chang JS; Lee KJ; Seong J
    Gut Liver; 2018 May; 12(3):342-352. PubMed ID: 29409306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
    Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
    BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer.
    Geng Y; Qi Q; Sun M; Chen H; Wang P; Chen Z
    Eur J Surg Oncol; 2015 Nov; 41(11):1508-14. PubMed ID: 26343824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer.
    Hu C; Bai Y; Li J; Zhang G; Yang L; Bi C; Zhao B; Yang Y; Li R; Wu H; Wang Q; Qin Y
    BMC Urol; 2020 May; 20(1):57. PubMed ID: 32460817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
    Faloppi L; Bianconi M; Giampieri R; Sobrero A; Labianca R; Ferrari D; Barni S; Aitini E; Zaniboni A; Boni C; Caprioni F; Mosconi S; Fanello S; Berardi R; Bittoni A; Andrikou K; Cinquini M; Torri V; Scartozzi M; Cascinu S;
    Oncotarget; 2015 Oct; 6(33):35087-94. PubMed ID: 26397228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
    Usul Afsar Ç; Karabulut M; Karabulut S; Alis H; Gonenc M; Dagoglu N; Serilmez M; Tas F
    J Infect Chemother; 2017 Apr; 23(4):196-200. PubMed ID: 28087305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
    Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
    Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
    Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
    J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
    Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.
    Wang P; Zhuang L; Zhang J; Fan J; Luo J; Chen H; Wang K; Liu L; Chen Z; Meng Z
    Mol Oncol; 2013 Jun; 7(3):334-45. PubMed ID: 23177026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
    Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
    BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.